Seres Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage biotechnology company focused on developing novel live biotherapeutic products (LBPs) designed to treat serious diseases by modulating the human microbiome. Following the strategic divestiture of its first FDA-approved oral microbiome therapeutic, VOWST, to Nestlé Health Science in September 2024, Seres has pivoted its core focus toward its emerging infectious and inflammatory (I&I) disease pipeline. The company's lead investigational candidate is SER-155, which has received Breakthrough Therapy and Fast Track designations from the FDA. SER-155 is designed to prevent bacterial bloodstream infections and graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Additionally, Seres is advancing SER-603 for inflammatory bowel disease (IBD) and maintaining its proprietary MbTx discovery platform.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Seres is shifting its operational focus to high-value, earlier-stage cultivated live biotherapeutic programs in inflammatory and immune diseases, such as SER-603 for inflammatory bowel disease (IBD), while pausing additional direct investment in its Phase 2-ready SER-155 program for allo-HSCT.
Expected impact: Allows the company to streamline its organization, focus on preclinical and early clinical assets, and preserve capital while seeking external funding or collaborators for larger trials.
Implementing a workforce reduction of approximately 30% and streamlining the organizational structure to align with the prioritized early-stage pipeline.
Expected impact: Significantly reduces recurring personnel and operational expenses to extend the company's cash runway.
Amended the lease agreement for the facility at 101 CambridgePark Drive in Cambridge, MA, reducing the leased square footage, rental rate, and building operating expense share (from 51.36% to 24.25%) over a new 10-year term.
Expected impact: Decreases aggregate lease payments by approximately $33.9 million, materially lowering ongoing annual facility-related cash costs and long-term lease liabilities.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Seres completed the sale of its VOWST microbiome therapeutic business to Nestlé Health Science in September 2024 to retire debt and fund operations. On June 2, 2026, the parties amended the agreement to buy out potential future sales-based milestones.
Terms: The original 2024 transaction included a $100 million upfront payment, a $15 million equity investment, and installment payments of $50 million (January 2025) and $25 million (July 2025). The June 2026 amendment provides Seres with a guaranteed $25 million cash payment (in two equal installments in July and October 2026) in exchange for buying out up to $275 million in potential future VOWST net sales-based milestones.
Collaborating on an investigator-sponsored clinical trial evaluating SER-155 in patients with immune checkpoint inhibitor-related enterocolitis (irEC).
Terms: Investigator-sponsored trial; specific financial terms not disclosed.